MaxCyte reports prelim Q4 total revenue $15.5-15.7M, core down YoY; FY total revenue $41.1-41.3M

MAXCYTE, INC.

2023-FY EPS reported -$0.37 revenue$41,288,000

Q4 2023 total revenue expected $15.5-15.7M (Q4 2022: $12.4M); core revenue $7.0-7.2M (down from $10.6M) and SPL revenue ~$8.5M (up from $1.9M).
FY 2023 total revenue expected $41.1-41.3M (FY 2022: $44.3M); core revenue $29.6-29.8M (down from $39.6M), SPL ~$11.4M (up from $4.6M).
Cash, equivalents and investments ~$210M as of Dec 31, 2023.
Management cited Vertex CASGEVY FDA approval as milestone validating platform; core revenue decline reflects cell therapy industry headwinds.
Results are preliminary, unaudited; audited statements expected in March 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. reported the fourth quarter ended December 31, 2023 results: revenue between $15.5 million and $15.7 million.

Period: the fourth quarter ended December 31, 2023
Revenue: between $15.5 million and $15.7 million
Result: preliminary results

Exact text from the filing

Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. reported the fiscal year ended December 31, 2023 results: revenue between $41.1 and $41.3 million.

Period: the fiscal year ended December 31, 2023
Revenue: between $41.1 and $41.3 million
Result: preliminary results

Exact text from the filing

Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-000136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.